DelveInsight’s ‘Hemophilia A Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Hemophilia A therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Hemophilia A pipeline domain.

 

To know more in detail about Hemophilia A pipeline report, click here: Hemophilia A Pipeline Insight

 

For Hemophilia A emerging drugs, the Hemophilia A pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

Key Takeaways from the Hemophilia A Pipeline Report

• Over 40+ Hemophilia A pipeline therapies are in various stages of development, and their anticipated acceptance in the Hemophilia A market would significantly increase market revenue.
• Leading Hemophilia A companies developing novel drug candidates to improve the Hemophilia A treatment landscape include Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, Novo Nordisk, Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd, Bayer, Ultragenix pharmaceutical, ApcinteX Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Expression Therapeutics, LLC, CSL Behring, ASC Therapeutics, Poseida Therapeutics, Staidson Beijing BioPharmaceuticals, Chia Tai Tianqing Pharmaceutical Group,  GeneVentiv Therapeutics, Jiangsu Gensciences, 2seventy bio, Generation Bio, Apitope Technology,  and others.
• Promising Hemophilia A pipeline therapies in various stages of development include  SPK-8011, SPK-8016, BIVV001, AGN-193408, Valoctocogene roxaparvovec, P-FVIII-101, STSP 0601, TQG203, SIG-001, Mim8, PF-07055480, Efanesoctocog alfa, WP 1301, Research program: gene therapies, GENV-HEM, Research program: gene editing therapeutics, NX-01, and others.
• In November 2022, CSL Limited announced that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc (“Arcturus Therapeutics”) to gain access to their late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology.
• In October 2022, the Food and Drug Administration accepted BioMarin Pharmaceutical’s latest approval application for a gene therapy designed to treat severe hemophilia A, and a decision date of March 31 has been set.

 

Request a sample and discover the recent breakthroughs happening Hemophilia A pipeline landscape: https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020

 

Hemophilia A Overview

Hemophilia is an inherited rare bleeding disorder in which blood does not clot properly because the affected person does not produce enough blood-clotting proteins (clotting factors). Patients who are injured cannot stop bleeding unless these factors are present. The severity of hemophilia symptoms is determined by the level of clotting factors. If the clotting factor level is mildly reduced, the patient may only bleed after surgery or trauma. If the deficiency is severe, one can easily bleed for no apparent reason. Small cuts are not dangerous, but internal bleeding is extremely dangerous for Hemophilia patients. Internal bleeding in the elbows, knees, ankles and other joints is the main concern with this genetic disorder. Internal bleeding can cause organ and tissue damage as well as be potentially fatal.

 

Hemophilia is classified into several types, including Hemophilia A, Hemophilia B, Hemophilia C, and Von Willebrand disease. Hemophilia is classified based on the presence of clotting factors, such as factor VIII in Hemophilia A and factor IX in Hemophilia B. Screening tests for hemophilia include the Complete Blood Count (CBC), Activated Partial Thromboplastin Time (APTT) Test, Prothrombin Time (PT) Test, Fibrinogen Test, and clotting factor tests.

 

Hemophilia A Pipeline Therapies and Key Companies

• Efanesoctocog alfa: Sanofi
• FRSW 107: Jiangsu Gensciences
• Mim8: Novo Nordisk
• SPK-8016: Spark Therapeutics
• OCTA101: Octapharma
• FRSW 117: Jiangsu Gensciences
• TQG203: Chia Tai Tianqing/Pharmaceutical Group
• STSP 0601: Staidson Beijing/BioPharmaceuticals
• P-FVIII-101: Poseida Therapeutics

 

Learn more about the Hemophilia A emerging pipeline therapies @ Hemophilia A Clinical Trials advancements

 

Hemophilia A Pipeline Therapeutics Assessment

By Product Type

• Monotherapy
• Combination Therapy

By Stage

• Discovery
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Pre-registration

By Route of Administration

• Oral
• Intravenous
• Subcutaneous

By Molecule Type

• Small molecules
• Gene Therapies
• Bispecific antibodies
• Recombinant proteins
• Fusion Proteins
• Coagulants
• Blood coagulation factor replacements

 

Scope of the Hemophilia A Pipeline Report

• Coverage: Global
• Key Hemophilia A Companies: Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, Novo Nordisk, Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd, Bayer, Ultragenix pharmaceutical, ApcinteX Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Expression Therapeutics, LLC, CSL Behring, ASC Therapeutics, Poseida Therapeutics, Staidson Beijing BioPharmaceuticals, Chia Tai Tianqing Pharmaceutical Group,  GeneVentiv Therapeutics, Jiangsu Gensciences, 2seventy bio, Generation Bio, Apitope Technology, and others.
• Key Hemophilia A Pipeline Therapies: SPK-8011, SPK-8016, BIVV001, AGN-193408, Valoctocogene roxaparvovec, P-FVIII-101, STSP 0601, TQG203, SIG-001, Mim8, PF-07055480, Efanesoctocog alfa, WP 1301, Research program: gene therapies, GENV-HEM, Research program: gene editing therapeutics, NX-01, and others.

 

Dive deep into rich insights for Hemophilia A emerging therapies and assessment; visit @ Hemophilia A Therapeutic Assessment

 

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Hemophilia A Pipeline Therapeutics

5. Late Stage Products (Phase III)

6. Mid Stage Products (Phase II)

7. Early Stage Products (Phase I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Hemophilia A Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Hemophilia A Unmet Needs

14. Hemophilia A Market Drivers and Barriers

15. Appendix

16. About DelveInsight

 

For further information on the Hemophilia A current pipeline therapeutics, reach out @ Hemophilia A Treatment Scenario

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services